Impact of circulating biomarkers in patients with metastatic colorectal cancer treated with first-line FOLFOX-aflibercept therapy. Results of the GERCOR VELVET Phase II study

Authors :: A. Tijeras-Raballand
A. De Gramont
M. Chiron
J.B. Bachet
T. André
D. Auby
J. Desramé
N. Baba-Ahmed
C. Lecaille
V. Lebrun
C. Louvet
C. Tournigand
S. Benner
M. Attia
F. Bonnetain
B. Chibaudel
Source :: European Journal of Cancer. 69:S147
Publication Year :: 2016
Publisher :: Elsevier BV, 2016.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
Colorectal cancer
First line
Phases of clinical research
medicine.disease
Circulating biomarkers
FOLFOX
Internal medicine
medicine
In patient
business
medicine.drug
Aflibercept

Full Text Access

Tools